Market Overview

SpinalCyte Announces Publication of Fibroblast Cell Therapy Review in the Journal of Translational Medicine

Share:

Showcases practicality of fibroblasts as an alternative to stem cells

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on
regrowth of the spinal disc using Human Dermal Fibroblasts, today
announced the publication of an analysis exploring the use of
fibroblasts as a more practical and potentially more effective cell
therapy than mesenchymal stem cells (MSCs). The article titled
"Fibroblasts as a Practical Alternative to Mesenchymal Stem Cells," was
published in the Journal of Translational Medicine and is available at https://translational-medicine.biomedcentral.com/track/pdf/10.1186/s12967-018-1536-1.

The review highlighted the need for cell therapies that are both
practical and commercially viable and explored the use of fibroblasts as
a more useful and potentially more effective cell therapy than
mesenchymal stem cells (MSCs). One immediate area of need for new
therapies is in degenerative disc disease (DDD). Degenerative disc
disease is a condition in which a patient's spinal disc breaks down and
can begin to collapse. It is estimated that 85% of people over the age
of 50 have evidence of disc degeneration and over 1.3 million procedures
a year are performed to treat the disease.

The most common treatments for patients with DDD are either discectomy
or spinal fusion. Discectomy is the partial or full removal of the
degenerated disc to decompress and relieve the nervous system but can
cause long term spinal pain. In a spinal fusion procedure, the entire
disc is removed and the two adjacent vertebrae are fused together. It
often increases strain on the adjacent discs and surrounding tissues
leading to further degeneration.

"Current therapies for DDD are inconsistent and expensive," said Thomas
Ichim, Ph.D., SpinalCyte Chief Scientific Officer and lead author of the
review. "A fibroblast cell therapy may be both clinically beneficial and
commercially attractive for patients with the disease. I have found that
the human dermal fibroblast product, CybroCell, is the most practical
and potent treatment for the disease I have worked with to date."

CybroCell is the first off-the-shelf allogenic human dermal fibroblast
(HDF) product for the treatment of degenerative disc disease.
SpinalCyte's Phase 1/Phase 2 clinical trial for injected human dermal
fibroblasts in the treatment of DDD demonstrated preliminary six-month
data whereby 83% of patients had an increase or no change in disc height.

"CybroCell addresses the underlying condition of degenerative disc
disease rather than just the symptoms. Such treatments may reduce or
eliminate the need for these patients to use addictive opioids," said
Pete O'Heeron, SpinalCyte Chief Executive Officer. "With over 85% of
patients using CybroCell reporting significant therapeutic improvement
at 6 months, we believe this therapy will ultimately lead to a cure for
DDD. In the future, we see HDFs replacing MSCs in other cell therapy
applications."

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine
company developing an innovative solution for spinal replacement using
human dermal fibroblasts. Currently, SpinalCyte holds 32 U.S. and
international issued patents and has filed for an additional 44 patents
pending. Funded entirely by angel investors, SpinalCyte represents the
next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.

View Comments and Join the Discussion!